{
    "nct_id": "NCT00824590",
    "title": "A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function",
    "status": "COMPLETED",
    "last_update_time": "2009-12-29",
    "description_brief": "This study is to compare the pharmacokinetics of Dimebon in subjects with severe renal impairment to subjects with normal renal function after oral administration of a single oral 20-mg dose of Dimebon. This study is also to assess the safety and tolerability of a single oral 20-mg dose of Dimebon in subjects with severe renal impairment and subjects with normal renal function.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "Cognitive enhancer",
    "drug": [
        "Dimebon (latrepirdine; PF-01913539)"
    ],
    "placebo": [
        "Placebo (matched)"
    ],
    "explanation_target": [
        "Reason: The intervention is Dimebon (latrepirdine/PF-01913539), a small\u2011molecule repurposed antihistamine that was investigated for improving cognition/neuroprotection in Alzheimer\u2019s disease rather than as a biologic targeting specific AD pathology (amyloid or tau). This places it conceptually as a cognitive enhancer under the provided definitions. \ue200cite\ue202turn0search7\ue202turn0search6\ue201",
        "Act: Key extracted details from the trial description \u2014 single oral 20 mg dose, Phase 1 PK/safety study in subjects with severe renal impairment vs normal renal function \u2014 match the user text. The drug identity and clinical program (latrepirdine = Dimebon = PF\u201101913539) are confirmed in clinical trial records and sponsor communications. Mechanistic studies and reviews describe unclear/pleiotropic mechanisms (neurotransmitter modulation, mitochondrial effects, autophagy) and observed cognitive effects in some trials, rather than a clear disease\u2011pathology (amyloid/tau) targeting mechanism. \ue200cite\ue202turn0search7\ue202turn0search0\ue202turn0search4\ue202turn0search8\ue201",
        "Reflect: Classification check \u2014 Dimebon is a small molecule (not a biologic), and its development focused on cognitive/functional benefit rather than a validated anti\u2011amyloid or anti\u2011tau mechanism; therefore it fits the 'Cognitive enhancer' category. It is not classified as a disease\u2011targeted small molecule under your definition because it was not developed as a specific amyloid/tau\u2011targeting modulator. Sources: clinical trial registry and peer\u2011reviewed reviews of latrepirdine/dimebon. \ue200cite\ue202turn0search7\ue202turn0search6\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The investigational agent is Dimebon (latrepirdine; PF\u201101913539), a small\u2011molecule repurposed Russian antihistamine that has been reported to act on multiple systems \u2014 low\u2011affinity NMDA/receptor actions, modulation of various neurotransmitter systems, mitochondrial effects and induction of autophagy \u2014 i.e., a pleiotropic/unclear single\u2011pathway mechanism rather than a focused anti\u2011amyloid or anti\u2011tau therapeutic. \ue200cite\ue202turn0search4\ue202turn0search7\ue202turn0search3\ue201",
        "Act: Key trial details and program context \u2014 Phase 1 single\u2011dose PK/safety study in subjects with severe vs normal renal function; drug identity confirmed as latrepirdine = Dimebon = PF\u201101913539; earlier clinical development showed an apparently positive Phase II but failed Phase III results \u2014 support that the agent was pursued as a cognitive enhancer/neuroprotective small molecule rather than a targeted anti\u2011amyloid/tau biologic. \ue200cite\ue202turn0search1\ue202turn0search4\ue201",
        "Reflect: Given the multiple reported mechanisms and the historical characterization of dimebon as a multitarget cognitive enhancer (with effects reported on autophagy, mitochondria, neurotransmission and receptor activity), the most appropriate CADRO classification is R) Multi\u2011target rather than a single\u2011mechanism CADRO category (e.g., A or B or D). This aligns with preclinical and clinical literature describing dimebon\u2019s pleiotropic/uncertain mechanism. \ue200cite\ue202turn0search2\ue202turn0search7\ue201",
        "Web search results (key sources cited above):",
        "\u2022 'The rise and fall of Dimebon' (review of clinical history and unclear mechanism). \ue200cite\ue202turn0search4\ue201",
        "\u2022 'Latrepirdine: a systematic review of the preclinical studies' (summarizes multiple targets including mitochondria, NMDA and neurotransmission). \ue200cite\ue202turn0search7\ue201",
        "\u2022 'Latrepirdine enhances autophagy \u2026' (preclinical evidence for autophagy/APP/A\u03b2 effects). \ue200cite\ue202turn0search3\ue201",
        "\u2022 Pfizer press release on Phase III results (CONNECTION program failed to show efficacy). \ue200cite\ue202turn0search1\ue201",
        "\u2022 'Acute dosing of latrepirdine \u2026 elevates extracellular amyloid\u2011\u03b2' / Molecular Neurodegeneration (evidence of pleiotropic effects on A\u03b2 dynamics and neurotransmission). \ue200cite\ue202turn0search2\ue201"
    ]
}